Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 30;15(12):2705.
doi: 10.3390/pharmaceutics15122705.

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy

Affiliations

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy

Beatriz Fernández-Rubio et al. Pharmaceutics. .

Abstract

Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria. However, it is hindered by the lack of stability data for the administration of antibiotics under OPAT conditions. Our objective was to investigate the stability of nine antipseudomonal and broad-spectrum beta lactam antibiotics (aztreonam, cefepime, cefiderocol, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem, meropenem/vaborbactam, and piperacillin/tazobactam) to allow the spread of OPAT programs. All the antibiotics were diluted in 500 mL 0.9% sodium chloride and stored at 4, 25, 32, and 37 °C for 72 h in two different devices (infusion bags and elastomeric pumps). The solutions were considered stable if the color, clearness, and pH remained unchanged and if the percentage of intact drug was ≥90%. All the antimicrobials remained stable 72 h under refrigerated conditions and at least 30 h at 25 °C. At 32 °C, all the antibiotics except for meropenem and meropenem/vaborbactam remained stable for 24 h or more. At 37 °C, only aztreonam, piperacillin/tazobactam, cefepime, cefiderocol, and ceftolozane/tazobactam were stable for at least 24 h. The stability results were the same in the two devices tested. All the antibiotics studied are actual alternatives for the treatment of antipseudomonal or multidrug-resistant infections in OPAT programs, although the temperature of the devices is crucial to ensure antibiotic stability.

Keywords: Pseudomonas aeruginosa; beta lactams; multidrug-resistant bacteria; outpatient parenteral antimicrobial therapy; stability.

PubMed Disclaimer

Conflict of interest statement

L.E.L.-C. has served as a scientific advisor for Angelini, a speaker for Angelini, ViiV, Gilead, and Correvio, and as a trainer for ViiV. A.d.A. has served as a scientific advisor for Angellini, Novartis, Roche, and Cook Medical, a speaker for MSD, Pfizer, Angellini, Novartis, Roche, and ViiV, and as a trainer for MSD and Cook Medical. The remaining authors have no conflict of interest to declare.

References

    1. Behzadi P., Ambrosi C., Scribano D., Zanetti S., Sarshar M., Gajdács M., Donadu M.G. Editorial: Current perspectives on Pseudomonas aeruginosa: Epidemiology, virulence and contemporary strategies to combat multidrug-resistant (MDR) pathogens. Front. Microbiol. 2022;13:975616. doi: 10.3389/fmicb.2022.975616. - DOI - PMC - PubMed
    1. Reynolds D., Kollef M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs. 2021;81:2117–2131. doi: 10.1007/s40265-021-01635-6. - DOI - PMC - PubMed
    1. Cramer N., Nawrot M.L., Wege L., Dorda M., Sommer C., Danov O., Wronski S., Braun A., Jonigk D., Fischer S., et al. Competitive fitness of Pseudomonas aeruginosa isolates in human and murine precision-cut lung slices. Front. Cell. Infect. Microbiol. 2022;12:992214. doi: 10.3389/fcimb.2022.992214. - DOI - PMC - PubMed
    1. WHO . Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis. World Health Organization; Geneva, Switzerland: 2017. WHO/EMP/IAU/2017.12.
    1. Breidenstein E.B.M., De La Fuente-Núñez C., Hancock R.E.W. Pseudomonas aeruginosa: All roads lead to resistance. Trends Microbiol. 2011;19:419–426. doi: 10.1016/j.tim.2011.04.005. - DOI - PubMed

LinkOut - more resources